Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003665467 | SCV004374760 | likely pathogenic | not provided | 2024-07-19 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with serine, which is neutral and polar, at codon 561 of the GALNT3 protein (p.Cys561Ser). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with tumoral calcinosis (PMID: 33614378). It has also been observed to segregate with disease in related individuals. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALNT3 protein function with a positive predictive value of 80%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Fulgent Genetics, |
RCV005030142 | SCV005652090 | likely pathogenic | Tumoral calcinosis, hyperphosphatemic, familial, 1 | 2024-03-21 | criteria provided, single submitter | clinical testing |